Won Seo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Won Seo Park has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Kyoung Sik Park
Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
5 shared publications - TongYi Jin
Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
4 shared publications - Ik Jin Yun
Department of Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
3 shared publications - Joon-Hyop Lee
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3 shared publications - Sang Eun Nam
Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
3 shared publications - Young Bum Yoo
Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 111 (4) , 203-207
The impact of the media coverage on the thyroid cancer overdiagnosis issue concerning the surgical trends in South Korea, 2012–2017: a retrospective multicenter cohort study
Lee JH, et al. Ann Surg Treat Res. 2026 Oct;111(4):203-207. https://doi.org/10.4174/astr.2026.111.4.203
- 1 January 2026
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 111 (4) , 203-207
Open AccessThe impact of the media coverage on the thyroid cancer overdiagnosis issue concerning the surgical trends in South Korea, 2012–2017: a retrospective multicenter cohort study
Lee JH, et al. Ann Surg Treat Res. 2026 Oct;111(4):203-207. https://doi.org/10.4174/astr.2026.111.4.203
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 106 (5) , 263-273
CTLA4 expression profiles and their association with clinical outcomes of breast cancer: a systemic review
Jin T, et al. Ann Surg Treat Res. 2024 May;106(5):263-273. https://doi.org/10.4174/astr.2024.106.5.263
- 1 January 2024
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 106 (5) , 263-273
Open AccessCTLA4 expression profiles and their association with clinical outcomes of breast cancer: a systemic review
Jin T, et al. Ann Surg Treat Res. 2024 May;106(5):263-273. https://doi.org/10.4174/astr.2024.106.5.263
- Open Access
- 8 November 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3480-3484
Efficacy of electroacupuncture in preventing nausea and vomiting after thyroidectomy: A prospective randomized controlled trial
- 8 November 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (9) , 3480-3484
Open AccessEfficacy of electroacupuncture in preventing nausea and vomiting after thyroidectomy: A prospective randomized controlled trial
- Open Access
- 7 October 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 103 (4) , 183-194
Vitamin D receptor (VDR) mRNA overexpression is associated with poor prognosis in breast carcinoma
Nam SE, et al. Ann Surg Treat Res. 2022 Oct;103(4):183-194. https://doi.org/10.4174/astr.2022.103.4.183
- 7 October 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 103 (4) , 183-194
Open AccessVitamin D receptor (VDR) mRNA overexpression is associated with poor prognosis in breast carcinoma
Nam SE, et al. Ann Surg Treat Res. 2022 Oct;103(4):183-194. https://doi.org/10.4174/astr.2022.103.4.183
- Open Access
- 29 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3754
BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
BRCA1/2 are breast cancer susceptibility genes that are involved in DNA repair and transcriptional control. They are dysregulated in breast cancer, making them attractive therapeutic targets. Here, we performed a systematic multiomics analysis to expound BRCA1/2 functions as prognostic biomarkers in breast cancer. First, using different web-based bioinformatics platforms (Oncomine, TIMER 2.0, UALCAN, and cBioportal), the expression of BRCA1/2 was assessed. Then, the R package was used to analyze the diagnostic value of BRCA1/2 in patients. Next, we determined the relationship between BRCA1/2 mRNA expression and prognosis in patients (PrognoScan Database, R2: Kaplan Meier Scanner and Kaplan–Meier Plotter). Subsequently, the association of BRCA1/2 with mutation frequency alteration and copy number alterations in breast cancer was investigated using the cBioportal platform. After that, we identified known and predicted structural genes and proteins essential for BRCA1/2 functions using GeneMania and STRING db. Finally, GO and KEGG pathway enrichment analyses were performed to elucidate the potential biological functions of the co-expression genes of BRCA1/2. The BRCA1/2 mRNA level in breast cancer tissues was considerably higher than in normal tissues, with AUCs of 0.766 and 0.829, respectively. Overexpression of BRCA1/2 was significantly related to the worse overall survival (p < 0.001) and was correlated to clinicopathological characteristics including lymph nodes, estrogen receptors, and progesterone receptors (p < 0.01). The alteration frequencies of both the gens have been checked, and the results show that BRCA1 and BRCA2 show different alteration frequencies. Their mutation sites differ from each other. GO and KEGG showed that BRCA1/2 was mainly enriched in catalytic activity, acting on DNA, chromosomal region, organelle fission, cell cycle, etc. The 20 most frequently changed genes were closely related to BRCA1/2, including PALB2 and RAD51 relatively. Our study provides suggestive evidence of the prognostic role of BRCA1/2 in breast cancer and the therapeutic target for breast cancer. Furthermore, BRCA1/2 may influence BRCA prognosis through catalytic activity, acting on DNA, chromosomal regions, organelle fission, and the cell cycle. Nevertheless, further validation is warranted.
- 29 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3754
Open AccessBRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
BRCA1/2 are breast cancer susceptibility genes that are involved in DNA repair and transcriptional control. They are dysregulated in breast cancer, making them attractive therapeutic targets. Here, we performed a systematic multiomics analysis to expound BRCA1/2 functions as prognostic biomarkers in breast cancer. First, using different web-based bioinformatics platforms (Oncomine, TIMER 2.0, UALCAN, and cBioportal), the expression of BRCA1/2 was assessed. Then, the R package was used to analyze the diagnostic value of BRCA1/2 in patients. Next, we determined the relationship between BRCA1/2 mRNA expression and prognosis in patients (PrognoScan Database, R2: Kaplan Meier Scanner and Kaplan–Meier Plotter). Subsequently, the association of BRCA1/2 with mutation frequency alteration and copy number alterations in breast cancer was investigated using the cBioportal platform. After that, we identified known and predicted structural genes and proteins essential for BRCA1/2 functions using GeneMania and STRING db. Finally, GO and KEGG pathway enrichment analyses were performed to elucidate the potential biological functions of the co-expression genes of BRCA1/2. The BRCA1/2 mRNA level in breast cancer tissues was considerably higher than in normal tissues, with AUCs of 0.766 and 0.829, respectively. Overexpression of BRCA1/2 was significantly related to the worse overall survival (p < 0.001) and was correlated to clinicopathological characteristics including lymph nodes, estrogen receptors, and progesterone receptors (p < 0.01). The alteration frequencies of both the gens have been checked, and the results show that BRCA1 and BRCA2 show different alteration frequencies. Their mutation sites differ from each other. GO and KEGG showed that BRCA1/2 was mainly enriched in catalytic activity, acting on DNA, chromosomal region, organelle fission, cell cycle, etc. The 20 most frequently changed genes were closely related to BRCA1/2, including PALB2 and RAD51 relatively. Our study provides suggestive evidence of the prognostic role of BRCA1/2 in breast cancer and the therapeutic target for breast cancer. Furthermore, BRCA1/2 may influence BRCA prognosis through catalytic activity, acting on DNA, chromosomal regions, organelle fission, and the cell cycle. Nevertheless, further validation is warranted.
- Open Access
- 19 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 863
Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA): Surgical Outcomes and Learning Curve
The transoral endoscopic thyroidectomy vestibular approach (TOETVA) has excellent cosmetic effects and its popularity is increasing worldwide. We present our experience with TOETVA and its short-term outcomes. This study included 110 consecutive patients who underwent TOETVA at a single institution between July 2016 and June 2020. We analyzed clinicopathologic data, short-term postoperative outcomes, and learning curve using cumulative summation (CUSUM) analysis. Of the 110 patients who underwent TOETVA, 101 had malignant disease and 100 (90.9%) underwent lobectomy. The mean age was 39.7 ± 9.7 years, and the mean tumor size was 1.0 ± 0.7 cm (range, 0.3–3.6 cm). Operation time was 168.0 ± 63.4 min for total thyroidectomy, 111.0 ± 27.7 min for lobectomy, and 73.7 ± 18.1 min for isthmusectomy. Five patients (4.5%) experienced transient vocal cord palsy (VCP) and one (0.9%) had permanent VCP. The swallowing impairment index-6 score was 2.18 ± 3.21 at postoperative three months, and 0.97 ± 1.72 at postoperative six months. The learning curve for lobectomy was 58 cases in CUSUM analysis. TOETVA is a safe and feasible approach with an acceptable operation time and a low complication rate. This approach is a surgical option for patients who desire excellent cosmesis.
- 19 February 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (4) , 863
Open AccessTransoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA): Surgical Outcomes and Learning Curve
The transoral endoscopic thyroidectomy vestibular approach (TOETVA) has excellent cosmetic effects and its popularity is increasing worldwide. We present our experience with TOETVA and its short-term outcomes. This study included 110 consecutive patients who underwent TOETVA at a single institution between July 2016 and June 2020. We analyzed clinicopathologic data, short-term postoperative outcomes, and learning curve using cumulative summation (CUSUM) analysis. Of the 110 patients who underwent TOETVA, 101 had malignant disease and 100 (90.9%) underwent lobectomy. The mean age was 39.7 ± 9.7 years, and the mean tumor size was 1.0 ± 0.7 cm (range, 0.3–3.6 cm). Operation time was 168.0 ± 63.4 min for total thyroidectomy, 111.0 ± 27.7 min for lobectomy, and 73.7 ± 18.1 min for isthmusectomy. Five patients (4.5%) experienced transient vocal cord palsy (VCP) and one (0.9%) had permanent VCP. The swallowing impairment index-6 score was 2.18 ± 3.21 at postoperative three months, and 0.97 ± 1.72 at postoperative six months. The learning curve for lobectomy was 58 cases in CUSUM analysis. TOETVA is a safe and feasible approach with an acceptable operation time and a low complication rate. This approach is a surgical option for patients who desire excellent cosmesis.
- Open Access
- 1 January 2021
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 100 (3) , 127-136
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
Park KS, et al. Ann Surg Treat Res. 2021 Mar;100(3):127-136. https://doi.org/10.4174/astr.2021.100.3.127
- 1 January 2021
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 100 (3) , 127-136
Open AccessSelective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
Park KS, et al. Ann Surg Treat Res. 2021 Mar;100(3):127-136. https://doi.org/10.4174/astr.2021.100.3.127
- Open Access
- 29 December 2020
- Published by Springer Nature in Research Square
Efficacy of Electroacupuncture in Preventing Nausea and Vomiting After Thyroidectomy: a Prospective Randomized Controlled Trial
Background: Postoperative nausea and vomiting (PONV) is regarded as a serious concern after thyroidectomy. Electroacupuncture (EA) shows potential to reduce general anesthesia-related side effects. The aim of this study was to evaluate the efficacy of EA in preventing PONV that commonly occurs in patients after thyroidectomy. Methods: This study was a prospective randomized controlled trial with a two-arm, parallel-group structure. Sixty-four participants were randomly assigned to the acupuncture (n=35) or control (n=29) group. Patients in the acupuncture group received EA and intradermal press needles at the ST36 and PC6 positions. The primary endpoint was the incidence and severity of PONV, and secondary endpoints were the length of hospital stay, pain severity, and postoperative in-hospital morbidity.Results: The total incidence of PONV was 40.6% (26/64). There was no difference in the incidence of PONV between the control (10/29, 34.5%) and acupuncture (16/35, 45.7%) groups (p = 0.362). Severity of PONV, as measured by VAS, was not different between the groups (p = 0.842). Length of hospitalization and postoperative complications were not different between the groups.Conclusion: In this randomized controlled trial, EA treatment after thyroidectomy is safe and comparable to conventional anti-emetic therapy. Trial registration: Clinical Research Information Service, KCT0001782. Registered on 26 January 2016.
- 29 December 2020
- Published by Springer Nature in Research Square
Open AccessEfficacy of Electroacupuncture in Preventing Nausea and Vomiting After Thyroidectomy: a Prospective Randomized Controlled Trial
Background: Postoperative nausea and vomiting (PONV) is regarded as a serious concern after thyroidectomy. Electroacupuncture (EA) shows potential to reduce general anesthesia-related side effects. The aim of this study was to evaluate the efficacy of EA in preventing PONV that commonly occurs in patients after thyroidectomy. Methods: This study was a prospective randomized controlled trial with a two-arm, parallel-group structure. Sixty-four participants were randomly assigned to the acupuncture (n=35) or control (n=29) group. Patients in the acupuncture group received EA and intradermal press needles at the ST36 and PC6 positions. The primary endpoint was the incidence and severity of PONV, and secondary endpoints were the length of hospital stay, pain severity, and postoperative in-hospital morbidity.Results: The total incidence of PONV was 40.6% (26/64). There was no difference in the incidence of PONV between the control (10/29, 34.5%) and acupuncture (16/35, 45.7%) groups (p = 0.362). Severity of PONV, as measured by VAS, was not different between the groups (p = 0.842). Length of hospitalization and postoperative complications were not different between the groups.Conclusion: In this randomized controlled trial, EA treatment after thyroidectomy is safe and comparable to conventional anti-emetic therapy. Trial registration: Clinical Research Information Service, KCT0001782. Registered on 26 January 2016.
- 1 February 2020
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 30 (2) , 175-182
Comparison Study of Robotic Thyroidectomies Through a Bilateral Axillo-Breast Approach and a Transoral Approach
Introduction: Oncological and surgical safeties are pivotal issues of cancer operations. Robotic thyroidectomy adds cosmetic advantage to those safeties. We have performed bilateral axillo-breast approach robotic thyroidectomies (BABART) since 2009 and recently started transoral robotic thyroidectomy (TORT) in 2017. This study aimed to compare the surgical outcomes of a single surgeon's initial TORT and BABART. Materials and Methods: We retrospectively collected data of 103 patients who underwent robotic thyroid lobectomy for papillary thyroid cancer and analyzed the first 14 and 56 cases of TORT and BABART, respectively, after propensity score matching. The surgeon performed 224 BABARTs before starting TORT. Results: There were no significant differences between the BABART and TORT groups in mean age (40.02 ± 9.37 versus 38.69 ± 9.21 years, respectively; P = .7520), sex distribution ( P = .3697), mean body mass index (23.60 ± 4.31 versus 23.87 ± 2.45 kg/m 2 , respectively; P = .4737), and tumor size (0.75 ± 0.35 versus 0.76 ± 0.29 cm, respectively; P = .9969). The TORT group had a longer operative time than the BABART group by 78.04 minutes ( P < .0001). The visual analog scale pain scores on postoperative day (POD) 2 and POD 3 were higher in the TORT than the BABART group by 0.59 and 0.77, respectively ( P = .0227 and .0119, respectively). The number of retrieved lymph nodes and unintended parathyroidectomies was similar in the two groups. There were no severe complications such as tracheal injury, transection of recurrent laryngeal nerve, or surgical site infection. Conclusion: Our study suggests that both BABART and TORT are safe and feasible during the initial period. TORT can be undertaken without any adverse event if the operator is experienced with other robotic thyroidectomy. The patients may choose the surgical approach based on their preference.
- 1 February 2020
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 30 (2) , 175-182
Comparison Study of Robotic Thyroidectomies Through a Bilateral Axillo-Breast Approach and a Transoral Approach
Introduction: Oncological and surgical safeties are pivotal issues of cancer operations. Robotic thyroidectomy adds cosmetic advantage to those safeties. We have performed bilateral axillo-breast approach robotic thyroidectomies (BABART) since 2009 and recently started transoral robotic thyroidectomy (TORT) in 2017. This study aimed to compare the surgical outcomes of a single surgeon's initial TORT and BABART. Materials and Methods: We retrospectively collected data of 103 patients who underwent robotic thyroid lobectomy for papillary thyroid cancer and analyzed the first 14 and 56 cases of TORT and BABART, respectively, after propensity score matching. The surgeon performed 224 BABARTs before starting TORT. Results: There were no significant differences between the BABART and TORT groups in mean age (40.02 ± 9.37 versus 38.69 ± 9.21 years, respectively; P = .7520), sex distribution ( P = .3697), mean body mass index (23.60 ± 4.31 versus 23.87 ± 2.45 kg/m 2 , respectively; P = .4737), and tumor size (0.75 ± 0.35 versus 0.76 ± 0.29 cm, respectively; P = .9969). The TORT group had a longer operative time than the BABART group by 78.04 minutes ( P < .0001). The visual analog scale pain scores on postoperative day (POD) 2 and POD 3 were higher in the TORT than the BABART group by 0.59 and 0.77, respectively ( P = .0227 and .0119, respectively). The number of retrieved lymph nodes and unintended parathyroidectomies was similar in the two groups. There were no severe complications such as tracheal injury, transection of recurrent laryngeal nerve, or surgical site infection. Conclusion: Our study suggests that both BABART and TORT are safe and feasible during the initial period. TORT can be undertaken without any adverse event if the operator is experienced with other robotic thyroidectomy. The patients may choose the surgical approach based on their preference.
- Open Access
- 3 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22–3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10–3.12; P = 0.02). Similar results were found in the discovery set. Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.
- 3 April 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Open AccessUpregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22–3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10–3.12; P = 0.02). Similar results were found in the discovery set. Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.